Cerenis lands $65M for mid-stage cholesterol drug program

Cerenis Therapeutics has nailed down $51.5 million in the first close of its Series C round, fueling the developer's mid-stage clinical trial for its lead cholesterol therapy and positioning the biotech for a potential regulatory submission in a little more than two years. Cerenis and Novasep, a contract manufacturer, simultaneously announced €10.7 million in funding from the French government for the lead drug program.   The latest round brings back a familiar group of...